Core Viewpoint - The stock price of Sely Medical has declined significantly, reflecting challenges in its financial performance and market perception [1] Company Overview - Sely Medical operates in the pharmaceutical commercial sector, focusing on intensive in vitro diagnostics and medical consumables supply chain management [1] - The company is attempting to transition into the AI healthcare field, particularly in brain science and large model technologies [1] Financial Performance - As of July 29, 2025, Sely Medical's stock price is 31.62 yuan, down 1.53 yuan or 4.62% from the previous trading day [1] - The company reported a net profit loss forecast of 55 million to 66 million yuan for the first half of the year, indicating a year-on-year increase in loss magnitude [1] - The company has recovered 4.2 million yuan of overdue equity transfer payments but still faces 9.3 million yuan in outstanding payments [1] Market Activity - On July 29, the net outflow of main funds was 204.55 million yuan, accounting for 3.39% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds reached 42.78 million yuan [1] Credit Rating - Rating agencies have downgraded Sely Medical's credit rating to BB+ [1]